pharma

Twitter to join S&P 500, replacing Monsanto

Twitter to join S&P 500, replacing Monsanto

Dow Jones Indices announced that Twitter Inc (NYSE: TWTR) will be joining the S&P 500 replacing Monsanto Company (NYSE: MON) in the index. Monsanto, an agrochemical and agricultural biotechnology corporation, will be removed from the S&..

Alibaba places shares into healthcare assets ($1.4 BILLION DEAL)

Alibaba places shares into healthcare assets ($1.4 BILLION DEAL)

Chinese e-commerce business Alibaba Group Holding Ltd (NYSE: BABA) sold some shares of pharmaceutical business to fund purchases of health-related assets through $1.4 billion deal.Alibaba Health Information Technology Ltd., a subsidiary of Alibaba, ..

Shire Shares Surge on Reports of Takeda Takeover Attempt

Shire Shares Surge on Reports of Takeda Takeover Attempt

Shire’s plc (NASDAQ: SHPG) shares surged by 17 percent on Wednesday following Takeda Pharmaceutical potential $40 billion bid midst acquisition and mergers in the pharmaceutical industry, according to CNBC.CNBC said Takeda is in its “pre..

Valeant Pharmaceuticals Posted Q4 Earnings

Valeant Pharmaceuticals Posted Q4 Earnings

On Wednesday, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced its financial results for the fourth quarter of 2017. With revenue missing estimates and earnings beating estimates, shares of the company dropped 9% to $16.84 per share..

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Inc. (NYSE: ABBV) reported its fourth quarter financial results for fiscal year 2017. The pharmaceutical company reported better than expected earnings sending shares 13.5 percent before market close on Friday.For the fourth quarter, AbbVie r..

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter financial results for fiscal year 2017. The U.S. drug-maker fell short on earnings estimates, but topped revenue estimates, sending shares 3 percent higher during Thursday’s pre-marke..

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..